Resources & FAQ
Frequently asked questions
Is LB6V approved?+
No. LB6V is an investigational vaccine that has not been approved by the FDA, EMA, or any other regulatory authority. Pfizer is planning regulatory submissions following the positive Phase 3 results.
When will LB6V be available?+
An availability timeline depends on regulatory review. No date has been confirmed. Sign up for updates to be notified.
Who can receive LB6V if approved?+
Clinical trials evaluated LB6V in individuals aged 5 years and older — particularly people living in or visiting Lyme-endemic regions.
How many doses are required?+
The Phase 3 schedule used a primary series of 3 doses followed by a booster dose.
Does the vaccine replace tick precautions?+
No. Even with vaccination, you should continue using insect repellent, wearing protective clothing in tick habitat, and performing tick checks.
What are the side effects?+
In Phase 3, LB6V was well tolerated with no new safety concerns. Full safety data will be published with peer-reviewed trial results.
Trusted links
Tick prevention tips
- • Use EPA-registered insect repellents containing DEET, picaridin, or IR3535.
- • Treat clothing and gear with 0.5% permethrin.
- • Walk in the center of trails and avoid tall grass.
- • Perform full-body tick checks within 2 hours of being outdoors.
- • Shower soon after coming indoors to wash off unattached ticks.